Swiss National Bank Has $54.79 Million Holdings in Hologic, Inc. (NASDAQ:HOLX)

Swiss National Bank cut its position in shares of Hologic, Inc. (NASDAQ:HOLX - Free Report) by 3.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 766,840 shares of the medical equipment provider's stock after selling 23,500 shares during the quarter. Swiss National Bank owned 0.33% of Hologic worth $54,791,000 at the end of the most recent quarter.

Other hedge funds also recently bought and sold shares of the company. First Trust Direct Indexing L.P. lifted its position in shares of Hologic by 15.8% in the fourth quarter. First Trust Direct Indexing L.P. now owns 7,629 shares of the medical equipment provider's stock worth $545,000 after purchasing an additional 1,043 shares in the last quarter. New York Life Investment Management LLC increased its holdings in Hologic by 0.7% in the fourth quarter. New York Life Investment Management LLC now owns 38,523 shares of the medical equipment provider's stock worth $2,752,000 after buying an additional 257 shares during the last quarter. Victory Capital Management Inc. increased its holdings in Hologic by 4.5% in the fourth quarter. Victory Capital Management Inc. now owns 5,055,048 shares of the medical equipment provider's stock worth $361,183,000 after buying an additional 216,958 shares during the last quarter. Savant Capital LLC increased its holdings in Hologic by 5.0% in the fourth quarter. Savant Capital LLC now owns 20,876 shares of the medical equipment provider's stock worth $1,492,000 after buying an additional 995 shares during the last quarter. Finally, Kestra Private Wealth Services LLC acquired a new position in Hologic in the fourth quarter worth approximately $224,000. 94.73% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the company's stock in a transaction on Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the transaction, the director now owns 48,611 shares of the company's stock, valued at approximately $3,670,130.50. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other Hologic news, Director Scott T. Garrett sold 16,441 shares of the business's stock in a transaction dated Thursday, March 14th. The stock was sold at an average price of $75.50, for a total transaction of $1,241,295.50. Following the completion of the sale, the director now directly owns 48,611 shares of the company's stock, valued at approximately $3,670,130.50. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Charles J. Dockendorff sold 1,465 shares of the company's stock in a transaction dated Friday, March 8th. The shares were sold at an average price of $76.21, for a total transaction of $111,647.65. Following the transaction, the director now owns 1,572 shares in the company, valued at $119,802.12. The disclosure for this sale can be found here. Insiders own 1.75% of the company's stock.

Hologic Price Performance

Shares of NASDAQ HOLX traded up $0.17 during midday trading on Tuesday, reaching $76.10. 984,581 shares of the company traded hands, compared to its average volume of 1,743,900. The firm has a market cap of $17.86 billion, a PE ratio of 38.74, a PEG ratio of 2.55 and a beta of 1.01. The stock's 50-day simple moving average is $76.15 and its 200-day simple moving average is $73.14. Hologic, Inc. has a 12 month low of $64.02 and a 12 month high of $86.74. The company has a debt-to-equity ratio of 0.52, a quick ratio of 3.29 and a current ratio of 3.97.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its quarterly earnings data on Thursday, May 2nd. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.98 by $0.05. Hologic had a return on equity of 18.91% and a net margin of 11.78%. The company had revenue of $1.02 billion during the quarter, compared to analysts' expectations of $1 billion. During the same period last year, the business earned $1.06 earnings per share. The business's revenue was down .8% on a year-over-year basis. As a group, equities analysts anticipate that Hologic, Inc. will post 4.08 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

HOLX has been the topic of several analyst reports. JPMorgan Chase & Co. increased their price target on Hologic from $85.00 to $91.00 and gave the company an "overweight" rating in a report on Friday. Evercore ISI raised their price objective on shares of Hologic from $76.00 to $78.00 and gave the stock an "in-line" rating in a research note on Thursday, April 4th. StockNews.com upgraded shares of Hologic from a "hold" rating to a "buy" rating in a research note on Friday. UBS Group raised their price objective on shares of Hologic from $78.00 to $79.00 and gave the stock a "neutral" rating in a research note on Friday, February 2nd. Finally, William Blair restated an "outperform" rating on shares of Hologic in a research note on Friday, February 2nd. Five equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and a consensus target price of $84.56.

Hologic Company Profile

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.